Please login to the form below

Not currently logged in
Email:
Password:

Amylin Pharmaceuticals cuts 340 jobs

San Diego-based biopharmaceutical company Amylin has announced that as part of a restructure it will slash its workforce by 25 per cent

San Diego-based biopharmaceutical company Amylin has announced that as part of a restructure it will slash its workforce by 25 per cent with an expectation of reducing expenditure by more than $80m.

The company was founded in 1987 and developed the diabetes treatments Symlin and Byetta. Amylin is in collaboration with Eli Lilly & Co on the global development and commercialisation of Byetta (exenatide) – however the company has stressed that this partnership is unaffected by the restructure.

"We've made a difficult, but necessary, decision as a result of factors affecting our business," said Daniel M Bradbury, president and CEO at Amylin Pharmaceuticals. "Sales revenues have not met the expectations we had when we scaled up our organisation. Today's actions will bring operating expenses more in line with revenue and enable us to continue to achieve our business goals of increasing sales of Byetta and Symlin and bringing exenatide once weekly to market as quickly as possible.

"The restructuring and workforce reductions impact administration, operations, and research and development. We continue to work closely with our partner Lilly to enhance the effectiveness and efficiency of the commercial organisation."

Following the restructure, the company will employ approximately 900 staff in San Diego, with a total of 1,800 staff worldwide.

12th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics